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ABSTRACT
Prevention of the effector cell activation via high affinity IgE receptor (FcεRI) is thought to be a straightforward
strategy for suppressing the allergic reaction. Among the numerous methods to prevent the activation through
FcεRI, three versions are described in this article. The first and second ideas involve inhibition of binding be-
tween FcεRI and IgE with a soluble form of the FcεRI α chain and a humanized antibody directed against the α
chain, respectively. Both of these paths involve suppression the histamine release from human peripheral
blood basophils in vitro. They also inhibited the allergic reaction in vivo. The soluble α inhibited the anaphylactic
reaction in rodents and the Fab fragments of the humanized anti-FcεRI α chain antibody suppressed the der-
mal response in rhesus monkeys. The third idea involves repression of FcεRI expression by suppressing the
transcription of the genes encoding the subunits of FcεRI. Although no plausible candidate molecule for actual-
izing this idea can be identified at present, further analyses of the transcriptional regulatory mechanisms in the
human FcεRI α and β chain genes will lead to the discovery of novel targets for developing anti-allergic agents．
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INTRODUCTION
The high affinity IgE receptor, FcεRI, plays a key role
in triggering the allergic reaction. FcεRI is composed
of three different subunits, α, β and γ, of which the α
chain directly binds IgE, while the β and γ chains me-
diate intracellular signals. Crosslinking of IgE-bound
FcεRI on the surface of effector cells such as mast
cells and basophils by the multivalent antigen in-
duces not only the release of chemical mediators in
the early phase reaction but also the expression of cy-
tokine genes leading to the late phase reaction .
Therefore the allergic reaction is thought to be effi-
ciently suppressed by intervention of initiation of acti-
vation signals from FcεRI. Many methods have been
considered for preventing stimulation through FcεRI,
for example, inhibition of binding between IgE and
FcεRI by blocking IgE(Fig. 1-1) or FcεRI(Fig. 1-2), in-
hibition of IgE production (Fig . 1-3), inhibition of
FcεRI expression (Fig . 1-4), etc . Here we will de-
scribe three models : ( 1 ) inhibition of IgE-FcεRI
binding by trapping IgE with a soluble form of the
FcεRI α chain, (2) inhibition of the IgE-FcεRI binding
by blocking the receptor with a humanized antibody
against the FcεRI α chain, (3) suppression of FcεRI
expression by regulating α and β chain gene tran-
scription.
RECOMBINANT SOLUBLE FORM OF THE
FcεRI α CHAIN
The α chain of FcεRI, a membrane-anchoring glyco-
sylated protein , binds IgE via its extracellular do-
main. A truncated form of the α chain containing 95%
of its extracellular domain was successfully ex-
pressed in Chinese hamster ovary (CHO) cells as a
secreted form, while retaining its binding activity for
IgE.1 The binding equilibration constant (KA) of this
recombinant soluble α chain and human IgE was
1010M in both surface plasmon resonance analyses
and scattered plotting . This value was almost the
same as the one between the cell surface FcεRI and
IgE. Furthermore, the stoichiometry of IgE binding
was confirmed to be 1 : 1 by gel filtration analyses of
the soluble α-IgE mixture.2
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Fig. 1　Candidate methods for preventing activation through FcεRI.
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Fig. 2　Prevention of the alergic reaction by the soluble  α chain.
①IgE is bound to Fc ε RI on mast cels. ② The first antigen entry after the administration of the soluble α chain causes 
crosslinking of FcεRI through IgE and activation of mast cels. ③ The crosslinked FcεRI is endocytosed and degraded in 
the lysosome. ④Newly synthesized FcεRI is expresed on the surface of mast cels, but it is unable to bind IgE which is 
trapped by the soluble α chain. ⑤ Repeated antigen invasion does not activate mast cels.4
lgE
Ag
solubleα
binding site for lgE
binding site for Ag
degradation in the lysosome
① ② ③ ④ ⑤
FcεRI
(γ2αβ)
The physiological activity of the soluble α chain
was examined both in vitro and in vivo. The soluble α
chain inhibited the release of histamine from human
peripheral blood basophils in a dose dependent man-
ner in vitro.1 In vivo, it suppressed PCA reactions in
the rat even if the soluble α chain treatment was per-
formed after IgE sensitization , although a larger
amount of the recombinant protein was required than
in pre-treatment before IgE sensitization. 1 The sol-
uble α chain also prevented death from anaphylactic
shock in a murine model when administered after
IgE sensitization. In addition, the short interval time
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Fig. 3　Inhibition of histamine release from human periph-
eral blood basophils by the Fab fragment of humanized anti-
human FcεRI α mAb.
After dissociating cel-bound immunoglobulins, leukocytes 
from human peripheral blood were preincubated with Fab 
fragments of humanized CRA2 or mouse CRA2. Cels were 
sensitized with human IgE folowed by stimulation with anti-
human IgE Ab.7
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between the administration of the soluble α chain and
the antigen challenge demonstrated no preventing ef-
fect, indicating that the soluble α chain could facili-
tate the dissociation of IgE from FcεRI on the cell sur-
face in addition to trapping free IgE.2 The soluble α
chain may have no effect on the activated mast cells
which have surface FcεRI already occupied by IgE
and crosslinked by the antigen, however it will act ef-
fectively when the crosslinked receptors are endocy-
tosed and empty receptors come up on the cell sur-
face because the presenting receptors are unable to
bind IgE in serum which has already been trapped by
the soluble α chain. In fact, this was proven by using
a novel murine model of type I allergy which was es-
tablished by transplantion of the hybridomas secret-
ing antigen-specific IgE in syngeneic mice.3 In this
model, administration of the soluble α chain before
the first antigen challenge and between the first and
second challenge suppressed the ear swelling re-
sponse in the second challenge but not in the first
challenge, which suggests that repeated administra-
tion of the soluble α chain may ultimately prevent the
allergic reaction in an IgE-sensitized individual ex-
posed to the repeated antigen invasion(Fig. 2).4
Additionally, the soluble α chain was shown to bind
to membranous IgE on the surface of B cells and to
specifically repress IgE production in B cells by in-
hibiting the mRNA expression of the mature ε chain.5
Although the negative signals elicited by the binding
of the soluble α to the surface IgE on B cells have not
been precisely characterized, the production of IL-6
from B cells was shown to be suppressed.6 It is there-
fore expected that the soluble α chain efficiently sup-
presses the allergic reaction not only by preventing
IgE-FcεRI binding on mast cells and basophils but
also inhibiting IgE production in B cells.
HUMANIZED ANTIBODY AGAINST THE
FcεRI α CHAIN
There is an another strategy for preventing IgE-
FcεRI binding by using a humanized anti-FcεRI α
chain antibody . A murine monoclonal antibody
against the human FcεRI α chain , CRA2, was suc-
cessfully humanized by CDR grafting to reduce the
antigenicity in humans.7 The humanized CRA2 had
almost the same binding activity for the α chain as
original CRA2 and showed reduced antigenicity in
Japanese monkeys.8 To prevent crosslinking of FcεRI
by antibodies which compete with IgE and cause acti-
vation of cells, Fab fragments of the humanized CRA2
were prepared in place of the whole antibody. The
Fab fragments of the humanized CRA2 suppressed
histamine release from the human peripheral blood
basophils in vitro (Fig . 3). 7 Furthermore , the Fab
fragments of the humanized CRA2 suppressed the
dermal reaction in rhesus monkeys through the local
intradermal administration.8
Although precise analyses of stability in vivo and
development of optimal administration methods are
required before initiation of clinical trials, the soluble
α chain and the humanized anti-FcεRI α chain anti-
body are expected to have suppressive activities
against allergy in humans, based on favorable results
in clinical trials using omalizumab (E25), a human-
ized anti-IgE antibody developed by GenentechNo-
vartisTanox which also inhibits the IgE-FcεRI bind-
ing.9,10
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Fig. 4　Structure of the human FcεRI α chain gene and transcription factors regulating gene expression.
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REGULATION OF THE FcεRI EXPRESSION
AT THE TRANSCRIPTIONAL LEVEL
In addition to preventing FcεRI-IgE binding, suppres-
sion of FcεRI expression can also inhibit the FcεRI
mediated allergic reaction. Due to the fact that the α
and β chains but not the γ chain of FcεRI are ex-
pressed specifically in the FcεRI expressing cells, the
expression of FcεRI would be specifically suppressed
by repressing the transcription of the α or β chain
gene. The α chain knockout mouse was reported to
have a significantly reduced anaphylactic response,11
indicating that the allergic reaction can be sup-
pressed by repression of α chain expression. Further-
more, intracellular signals mediated by the γ chain, as
well as the cell surface expression of the receptors,
are amplified in the presence of the β chain,12-14 al-
though functional receptors are expressed both as te-
trameric (αβγ2) and trimeric (αγ2) forms in humans.15
These facts add further support to the argument that
repression of the β chain expression raises the
threshold of the induction of the allergic reaction.
Tanscriptional regulatory mechanisms of the hu-
man FcεRI α and β chain genes have recently been
analyzed. As for the α chain (Fig. 4), both the regula-
tory elements close to the promoter region and the
associated transcription factors binding to them have
been identified. 16,17 GATA-1 cooperatively activated
the α chain promoter with PU.1 and YY-1 transcrip-
tion factors, while Elf-1 suppressed it by competing
for the recognition site with PU.1 and YY-1. This was
due to the fact that the binding site of Elf-1 partially
overlaps with the PU.1 and YY-1 sites.17 On the other
hand, an element in the first intron was identified as
an enhancer which was bound by a complex of USF
1USF 2. Moreover , USF 2 antisense actually re-
pressed the α chain expression.18 In addition, two
novel exons were found at 18.4 kb and 12.6 kb up-
stream of the reported first exon. These exons were
shown to be transcribed, which indicates the pres-
ence of an additional distal promoter.19 Although the
activity of the distal promoter seemed to be weaker
than the major promoter located upstream of the pre-
viously reported first exon, upregulation of α chain
expression by IL-4 is possibly mediated by this distal
promoter as evidenced by the fact that mRNA con-
taining the novel two exons was increased by IL-4
stimulation.20
On the other hand , the analyses of the human
FcεRI β chain gene region around the transciption in-
itiation site revealed that two Oct-1 recognition sites
were required for cell-type specific transcriptional ac-
tivation.21 And recently, the transcription factor MZF-
1 was found to suppress β chain gene expression via
an element in the fourth intron.22
Finally, although there is currently no concrete evi-
dence of a candidate molecule which specifically in-
hibits the expression of the genes encoding FcεRI at
present, it is hoped that the progress of the above
mentioned studies will lead the way to the discovery
of specific novel targets for agents against allergy.
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